BMC Cancer (Oct 2018)

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

  • Cindy Canivet,
  • Sophie Gourgou-Bourgade,
  • Bertrand Napoléon,
  • Laurent Palazzo,
  • Nicolas Flori,
  • Pierre Guibert,
  • Guillaume Piessen,
  • Dominique Farges-Bancel,
  • Jean-François Seitz,
  • Eric Assenat,
  • Véronique Vendrely,
  • Stéphanie Truant,
  • Geoffroy Vanbiervliet,
  • Philippe Berthelémy,
  • Stéphane Garcia,
  • Anne Gomez-Brouchet,
  • Louis Buscail,
  • Barbara Bournet,
  • The BACAP Consortium

DOI
https://doi.org/10.1186/s12885-018-4906-4
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background The prognosis for pancreatic cancer remains poor despite diagnostic advances and treatments with new chemotherapeutic regimens. The five year survival rate remains below 3%. Consequently, there is an urgent need for new treatments to significantly improve the prognosis. In addition, there is a big gap in terms of the screening, early diagnosis and prevention of pancreatic cancer the incidence of which is increasing dramatically. Methods Design: the BACAP cohort is a prospective multicenter pancreatic cancer cohort (pancreatic ductal carcinoma) with clinical and multiple biological samples; Participating centers: 15 French academic and private hospitals; Study Population: any cytologically and/or histologically proven pancreatic carcinoma regardless of the stage (resectable, borderline, locally advanced or metastatic) or treatment (surgery, palliative chemotherapy, best supportive care). At least 1500 patients will be included. Clinical data collected include: disease presentation, epidemiological and social factors, baseline biology, radiology, endoscopic ultrasound, staging, pathology, treatments, follow-up (including biological and radiological), and survival. All these data are collected and stored through an e-observation system at a centralized data center. Biological samples and derived products (i.e. before any treatment): blood, saliva, endoscopic ultrasound-guided fine needle aspiration materials from the primary tumor, fine needle biopsy of metastases and surgically resected tissue. DNA and RNA are extracted from fine needle aspiration materials and are quantified and characterized for quality. Whole blood, plasma and serum are isolated from blood samples. Frozen tissues were specifically allocated to the cohort. All derived products and saliva are stored at − 80 °C. Main end-points: i) to centralize clinical data together with multiple biological samples that are harmonized in terms of sampling, the post sampling process and storage; ii) to identify new molecular markers for the diagnosis, prognosis and possibly the predictive response to pancreatic cancer surgery and or chemotherapy. Discussion The BACAP cohort is a unique prospective biological clinical database that provides the opportunity to identify correlations between the presence/expression of a broad panel of biomarkers (DNA, RNA, miRNA, proteins, etc.), epidemiological and social data, various clinical situations, various stages and the differentiation of the tumor, treatments and survival. Trial registration ClinicalTrials.gov Identifier: NCT02818829. Registration date: June 30, 2016.

Keywords